NCT00210548View on ClinicalTrials.gov

A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

April 30, 2005

Study Completion Date

June 30, 2006

Conditions
Schizophrenia
Interventions
DRUG

paliperidone palmitate

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00210548 - A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia | Biotech Hunter | Biotech Hunter